Jeffrey A. Engelman
M.D., Ph.D.
Global Head of Oncology
👥Biography 个人简介
Jeffrey Engelman is an expert in cancer drug resistance mechanisms who leads oncology research at Novartis. His academic work at Massachusetts General Hospital characterized mechanisms of EGFR inhibitor resistance in lung cancer, identifying MET amplification and other bypass pathways that inform combination strategies.
Jeffrey Engelman是癌症药物耐药机制专家，领导诺华的肿瘤学研究。他在麻省总医院的学术工作描述了肺癌中EGFR抑制剂耐药的机制，鉴定了MET扩增和其他旁路通路，为组合策略提供信息。
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Resistance Mechanisms
Identified MET amplification as bypass mechanism of EGFR inhibitor resistance.
Combination Strategies
Developed rational combinations to prevent or overcome resistance.
Representative Works 代表性著作
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Science (2007)
Discovery of MET bypass resistance mechanism.
📄Data Sources 数据来源
Last updated: 2026-03-05 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Jeffrey A. Engelman 的研究动态
Follow Jeffrey A. Engelman's research updates
留下邮箱，当我们发布与 Jeffrey A. Engelman（Novartis Institutes for BioMedical Research）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment